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Abstract: c-Raf is a central component of the extracellular signal-regulated kinase (ERK) pathway
which is implicated in the development of many cancer types. RanBPM (Ran-Binding Protein
M) was previously shown to inhibit c-Raf expression, but how this is achieved remains unclear.
RanBPM is part of a recently identified E3 ubiquitin ligase complex, the CTLH (C-terminal to LisH)
complex. Here, we show that the CTLH complex regulates c-Raf expression through a control of its
degradation. Several domains of RanBPM were found necessary to regulate c-Raf levels, but only the
C-terminal CRA (CT11-RanBPM) domain showed direct interaction with c-Raf. c-Raf ubiquitination
and degradation is promoted by the CTLH complex. Furthermore, A-Raf and B-Raf protein levels are
also regulated by the CTLH complex, indicating a common regulation of Raf family members. Finally,
depletion of CTLH subunits RMND5A (required for meiotic nuclear division 5A) and RanBPM
resulted in enhanced proliferation and loss of RanBPM promoted tumour growth in a mouse model.
This study uncovers a new mode of control of c-Raf expression through regulation of its degradation
by the CTLH complex. These findings also uncover a novel target of the CTLH complex, and suggest
that the CTLH complex has activities that suppress cell transformation and tumour formation.
Keywords: c-Raf; CTLH complex; RanBPM; RMND5A; ubiquitination; cancer; ERK pathway

1. Introduction
Hyperactivation of the extracellular signal-regulated kinase (ERK) signaling pathway occurs
in up to one third of human cancers of various origins and promotes cell proliferation, survival
and transformation through activation of signaling pathways targeting various cytoplasmic and
nuclear targets [1–3]. Central to these pathways are the Raf kinases, of which three isoforms exist
in mammals, A-Raf, B-Raf and c-Raf which share a common structure [3]. Each isoform consists of
three conserved regions (CR), each possessing their own distinct function necessary to the activity and
regulation of the Raf kinases. CR1 contains the Ras binding domain necessary for Ras binding and
subsequent attachment to the plasma membrane for activation. CR2 contains activating and inhibitory
phosphorylation sites regulating Ras binding and Raf activation, while CR3 contains the kinase
domain, which is activated upon phosphorylation of the activating segment contained in the CR3 [4–6],
reviewed in [2]. While B-Raf has the highest occurrence of mutations in human cancers and therefore
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appears to have a dominant role in the ERK signaling pathway, c-Raf, also known as Raf-1, has been
the most extensively studied and thus is the best characterized Raf kinase [2]. c-Raf activation is
tightly regulated through a complex regulatory process involving phosphorylation/dephosphorylation
events, translocation to the membrane, and subsequent homo- or heterodimerization [2]. During
the inactive state, c-Raf is held in a closed conformation by the N-terminal regulatory region folding
over the C-terminal catalytic domain, with the 14-3-3 dimer stabilizing the conformation by binding
phosphorylated S259 (pS259) of the N-terminal, and pS621 of the C-terminal [2]. Activation is initiated
by pS259 dephosphorylation, releasing 14-3-3 from the N-terminal and revealing the Ras binding sites
allowing for Ras binding and recruitment to the plasma membrane [5,7]. The activation segment of
CR3 is then phosphorylated, specifically at S338, to achieve full kinase activation with Raf homo- or
heterodimerization, leading to its subsequent interaction with MEK [8,9]. Dimerization is required for
Raf activation. Heterodimerization of c-Raf and B-Raf was demonstrated to occur following mitogen
activation, while A-Raf weakly dimerizes with B-Raf [8,10]. In addition, the interaction between Heat
Shock Protein 90 (Hsp90) and c-Raf is essential to c-Raf stability and its activity as a signal transducer
within the ERK signaling pathway [11,12]. c-Raf stability is also regulated through ubiquitination by
CHIP (C-terminus of constitutive heat shock protein (Hsc) 70-interacting protein), a highly conserved
E3 ubiquitin ligase, which associates with the molecular chaperone proteins Hsc70–Hsp70 and Hsp90
causing client proteins to be ubiquitinated and subsequently degraded via the proteasome [13,14].
X-linked inhibitor of apoptosis proteins (XIAP), another E3 ubiquitin ligase, has also been found to
interfere with c-Raf stability, promoting ubiquitination through Hsp90-mediated CHIP, independent
of its own E3 ligase activity [15].
Interestingly, incidences of CHIP-independent modes of ubiquitination of c-Raf have been
documented. For successful activation of C-Raf, S621 must be autophosphorylated in order to allow
for correct folding and stability, as pS621 is necessary to bind 14-3-3 to its C-terminal [16]. Without
the phosphorylation of S621, c-Raf is effectively kinase-dead and is degraded by the proteasome [17].
However, degradation is not exclusively regulated by CHIP, as siRNA knockdown of CHIP did
not yield altered levels of kinase-dead c-Raf [17]. Treatment with the oxidative glucose metabolite
methylglyoxal and abolishing extracellular adhesion has been shown to cause degradation of c-Raf
through the ubiquitin-proteasome system [18,19]. However, the E3 ubiquitin ligase was not identified
in either case.
A lesser-known regulator of c-Raf stability is the protein RanBPM (Ran-Binding Protein M), which
was initially identified to bind the c-Raf kinase domain in a yeast two-hybrid analysis [20]. Subsequently,
our studies showed that RanBPM and c-Raf form a complex and that RanBPM downregulates c-Raf at
the protein level [21]. RanBPM also had a repressive effect on ERK phosphorylation, suggesting that,
through its effect on c-Raf, RanBPM is an inhibitor of the ERK pathway [21]. However, the mechanism
by which RanBPM downregulates c-Raf remains unknown. RanBPM has been previously been
implicated in the regulation of several cancer pathways and has been suggested to have tumour
suppressive functions [22,23]. While initially studied in isolation, it has now become evident that
RanBPM is part of a large complex called the C-terminal to LisH (CTLH) complex that has E3 ligase
activity [23,24]. However, the targets and activities of the CTLH complex are still largely unknown.
In this study, we show that downregulation or knockout of CTLH complex subunits RanBPM and
RMND5A (Required for Meiotic Nuclear Division 5A) lead to increased cell proliferation and that
RanBPM downregulation promotes tumour formation in a mouse tumour model. We show that
RanBPM binds c-Raf directly and that this interaction is dependent on the RanBPM C-terminal CRA
(CT11-RanBPM) domain. The stability of all three Raf kinases (A-Raf, B-Raf and c-Raf) was found to
be dependent on CTLH complex member RMND5A expression and c-Raf ubiquitination is regulated
in a CTLH complex-dependent manner. Overall, this study uncovers a novel regulation of c-Raf by the
CTLH complex that may contribute to the tumour-suppressive activity of this novel E3 ligase complex.
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2. Results
2.1. CTLH Complex Members Regulate c-Raf Levels and Cell Growth
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p < 0.05 (*). (B) RMND5A regulates ERK signaling. Whole cell extracts from WT HEK293 cells and
CRISPR KO RMND5A HEK293 cells were analyzed by Western blot for ERK and MEK phosphorylation.
The same extracts were run on two different gels and equal loading was assessed for both analyses
using total ERK and total MEK and a tubulin antibody. (C) RMND5A knockout HEK293 cells show
increased proliferation. Growth rates for HEK293 control (WT, blue) and three different RMND5A
CRISPR KO cell lines (clones #1, red, 3, green and 14, purple) were assessed for six days. Data represents
average cell number from at least three experiments with error bars indicating SEM. p < 0.05 (*), p < 0.01
(**), p < 0.001 (***); (D) c-Raf expression is increased in primary RanBPM knockout mouse embryonic
fibroblasts (MEFs). MEFs were isolated from RanBPM WT, and knockout (KO) embryos at D13.5. In the
top, whole cell extracts were analyzed by Western blot with antibodies to RanBPM, c-Raf and β-actin.
Below, quantification of relative amounts of c-Raf normalized to β-actin. Results are averaged from 13
paired MEFs samples from five different sets of embryos with error bars indicating SEM. p < 0.05 (*);
(E) RanBPM knockout MEFs proliferate faster than WT MEFs. Growth rates for primary wildtype (WT,
blue) and RanBPM knockout (KO, red) MEFs were assessed for five days. Data represents average
cell number from three independent experiments performed in triplicate. Error bars represent SEM.
p < 0.01 (**), p < 0.001 (***).

As RanBPM downregulation was previously reported to result in increased cellular
proliferation [21,26], we evaluated whether the loss of RMND5A could also confer similar properties.
Comparison of growth curves of wild-type (WT) and three different RMND5A CRISPR knockout
HEK293 clonal derivatives showed that control cells slowed down after four days, whereas cells lacking
RMND5A proliferated markedly faster starting at day 3 (Figure 1C). We also determined that, similar
to the loss of RanBPM that we previously showed induced MEK and ERK phosphorylation [21],
the knockout of RMND5A resulted in increased MEK and ERK phosphorylation (Figure 1B).
Interestingly, we found that primary mouse embryonic fibroblasts (MEFs) isolated from RanBPM KO
mice also displayed increased c-Raf expression and increased proliferation (Figure 1D,E), suggesting
that the consequences of the loss of RanBPM/CTLH complex are not restricted to immortalized cells.
2.2. RanBPM Expression Prevents Tumour Formation in Mouse Models
Our observations that RanBPM downregulation promotes c-Raf expression and ERK activation [21]
suggested that loss of RanBPM function could promote tumour formation in vivo. Moreover,
downregulation of RanBPM in Hela and HCT116 cells causes extensive changes in the expression of
several genes implicated in oncogenesis [27]. In particular, overexpression of RON (Recepteur d’origine
nantais) kinase, L1 cell adhesion molecule (L1CAM), ELF3 (E74-like factor 3), transglutaminase 2 (TG2)
(all increased in RanBPM shRNA cells [27]) have all been reported in various tumour types and were
shown to be directly implicated in cancer development [28–31]. Thus, loss of RanBPM affects several
pathways which collectively promote many aspects of tumorigenesis.
We tested whether RanBPM downregulation could promote tumour formation in a xenograft
model. For this assay, we generated a pool of early passage HEK293 cells stably expressing
RanBPM shRNA or control shRNA (Figure 2A). HEK293 cells are immortalized with Adenovirus
5 E1A expression but exhibit weak tumorigenicity [32]. RanBPM shRNA HEK293 injected into
NOD/SCID/gamma (NSG) mice caused a marked and statistically significant increase in tumour
volume over control cells (Figure 2C). Tumours also appeared earlier (day 17, versus day 31) and were
on average twentyfold larger (220 mm3 versus 11 mm3 ) than those observed with control cells at day 35.
These results suggest that RanBPM downregulation can enhance tumorigenic properties of HEK293
cells in this model. To demonstrate that these effects were not due to off-target effects of the RanBPM
shRNA, we generated HEK293 RanBPM shRNA cells with stably integrated Tetracyclin (Tet)-off
vector pBIG-RanBPM in which RanBPM can be re-expressed upon removal of Tet/doxycycline (Dox)
(Figure 2A, lanes 3,4). We verified that re-expression of RanBPM reduced ERK phosphorylation to
wild-type levels (Figure 2B). Interestingly, RanBPM shRNA cells also showed an upregulation of A-Raf
and B-Raf protein levels, which specifically decreased upon re-expression of RanBPM, suggesting that

Int. J. Mol. Sci. 2019, 20, 934

5 of 20

ERK pathway activation could result from all three Raf kinases activation in these cells. pBIG RanBPM
shRNA cells were injected into NSG mice. Mice fed with Dox-containing chow developed tumours,
whereas those fed with regular chow did not, demonstrating that RanBPM re-expression effectively
prevents
formation
(Figure 2D).
Int.tumour
J. Mol. Sci. 2019,
19, x
5 of 20
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2.4. The N-Terminus, CRA and LisH/CTLH Domains of RanBPM Are Required for c-Raf Downregulation
Given that RanBPM contains a number of conserved domains, we sought to determine which
regions of RanBPM were necessary for downregulation of c-Raf. We used a series of RanBPM deletion
mutant constructs (Figure 4A) sub-cloned into the mammalian expression vector pCMV-HA [34,36],
to test their effects on levels of c-Raf. ∆N-c-Raf, a constitutively active construct of c-Raf containing
only amino acids 325–648 [9], was used instead of full-length c-Raf because RanBPM has been shown
to have a greater effect on activated c-Raf [21]. Since RanBPM is able to dimerize [37], we performed
the experiments in HeLa RanBPM shRNA cells to avoid dimerization between mutant RanBPM
and endogenous WT RanBPM monomers. As previously reported [21], WT RanBPM was able to
significantly downregulate ∆N-c-Raf compared to the levels of ∆N-c-Raf seen in the pCMV-HA control
(Figure 4B). The RanBPM deletion mutant ∆212, in which the SPRY domain is deleted, was also able to
downregulate ∆N-c-Raf, indicating that the SPRY domain is not required for c-Raf destabilization.
Next, we tested the effect of N-terminal deletions of RanBPM. We previously reported that ∆N2
RanBPM is expressed at lower levels than WT RanBPM [36], which made the results difficult to
evaluate since lower expression levels may have accounted for the inefficiency of this mutant to
regulate ∆N-c-Raf. However, even in experiments where higher levels of ∆N2 RanBPM were obtained,
∆N2 RanBPM was unable to effectively downregulate ∆N-c-Raf (Figure 4B). Therefore, ∆N2 RanBPM
appeared to have lost its ability to downregulate ∆N-c-Raf, implying that the N-terminus of RanBPM
is required for its effect on c-Raf.
The ∆360 and ∆C4 RanBPM mutants also did not effectively downregulate ∆N-c-Raf, as ∆N-c-Raf
expression levels were significantly higher than those seen in response to WT RanBPM, and not
significantly different than those seen in the pCMV-HA control (Figure 4B). This occurred despite
the fact that expression of these mutants was noticeably higher than that of WT RanBPM. These
results suggest that the LisH/CTLH domains and the C-terminus of RanBPM play a role in c-Raf
downregulation. However, considering that the ∆C4 deletion removes a very large portion of RanBPM,
we repeated the experiment using a construct harboring only a deletion of the CRA domain, namely
the ∆C1 RanBPM construct. Like ∆C4, ∆C1 was unable to downregulate ∆N-c-Raf (Figure 4C).
This implies that, within the C-terminus of RanBPM, it is specifically the CRA domain that is needed
for c-Raf downregulation.
Altogether, these results demonstrate that the N-terminus, LisH/CTLH and CRA domains are
required for c-Raf destabilization, since loss of any of these regions render RanBPM unable to effectively
downregulate c-Raf.
2.5. The CRA Domain of RanBPM Is Required for Interaction with c-Raf
Next, we aimed to determine the RanBPM domain(s) required for interaction with c-Raf.
To accomplish this, we co-transfected either GST or GST-∆N-c-Raf with RanBPM deletion mutants
in RanBPM shRNA HeLa cells and performed GST pull-down assays. Due to its poor stability,
∆N2 RanBPM was not tested as we were unable to obtain sufficient levels of the protein to detect
it in this type of assay. As anticipated based on previous studies [21], GST-∆N-c-Raf was able to
successfully pull-down WT RanBPM (Figure 4D). Both ∆212 RanBPM and ∆360 RanBPM associated
with ∆N-c-Raf similar to WT, indicating that that the SPRY and LisH/CTLH domains are not required
for the interaction between RanBPM and c-Raf (Figure 4D,E). However, ∆C1 RanBPM was not able to
effectively interact with ∆N-c-Raf, showing a twofold decrease compared to WT RanBPM (Figure 4D).
Thus, the data suggest that, of the domains tested here, the CRA domain is the only one required for
the interaction between RanBPM and c-Raf.
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2.6. RanBPM Interacts Directly with c-Raf through the CRA Domain
To confirm the interaction between the CRA domain of RanBPM and c-Raf and determine whether
the interaction is direct, we performed pull-down experiments using bacterially expressed mammalian
c-Raf and RanBPM. In addition to full-length RanBPM, we tested RanBPM C1 (encoding only the CRA
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GST-RanBPM constructs were purified on glutathione beads and incubated with a crude cell
lysate from E. coli expressing ∆N-c-Raf. Both GST-WT-RanBPM and GST-C1 were able to pull-down
∆N-c-Raf (Figure 5B), indicating that the interaction between RanBPM and c-Raf is direct and that the
CRA domain is sufficient for the interaction. GST-N2 was unable to pull-down ∆N-c-Raf (Figure 5B),
suggesting that the N-terminus of RanBPM is unable to directly interact with c-Raf.
2.7. Analysis of the RanBPM CRA Domain Interaction with c-Raf
To identify sub-domains that might mediate interaction with c-Raf, we examined structural
features of the CRA domain to design partial deletions. As there is no crystal structure of RanBPM or
the CRA domain currently available, a predicted tertiary structure was elucidated by the RAPTORX
online server [38]. The predicted tertiary structure corroborated the previous assumption that
the CRA domain has a high propensity for α-helices, with 6 α-helices spanning the entirety of
the domain [23,39] (Figure S1A). Deletion mutants of the RanBPM CRA domain were created to
identify sub-domains that might mediate interaction with c-Raf (Figure 5C). Deletions were guided
by thepredicted tertiary structure (Figure S1B) and data shown above demonstrating that amino
acids 649–729 of RanBPM, denoted C1, bound directly to ∆N-c-Raf (Figure 5B). Only a portion of
the CRA domain is present in the C1 construct, namely helices IV, V and VI, and a small portion of
helix III. We therefore derived two GST-fusion CRA constructs which contained amino acids 615–669
spanning helices I, II, and III, denoted C1-1, and amino acids 663–729 containing helices IV, V, and VI,
denoted C1-2. GST pull down assays were normalized to the negative control, GST, and compared
to the positive ∆N-c-Raf binding control, GST-C4, which contains amino acids 471–729 of RanBPM.
(Figure 5C, representative experiments shown in Figure S2A). GST-C1 displayed significant interaction
with ∆N-c-Raf, although quantifications showed reduced binding compared to GST-C4, by 2.5-fold.
Both GST-C1-1 and GST-C1-2 appeared to lack protein stability as they bound less ∆N-c-Raf than that
of the GST negative control.
To increase protein stability, CRA domain constructs were expanded to include sequences
N-terminal to the CRA domain (Figure 5C). Similar to the strategy used for the two previous constructs,
CRA deletion mutations were guided by the predicted tertiary structure. We derived an additional
four GST-fusion CRA constructs: C4A which spans amino acids 471–639 and helices I and II; C4B
contains amino acids 471–669 and helices I–III; C4C is comprised of amino acids 471–692 and helices
I–IV; and finally, C4D which includes amino acids 471–639 and 671–729, and helices I–II and IV–VI.
∆N-c-Raf binding was again tested by GST pull down assay and the mutants binding to ∆N-c-Raf
were quantified and compared to that of GST-C4 (Figure 5C and Figure S2B). All mutants showed
decreased binding compared to C4, suggesting that each helix of the CRA domain plays a role in
binding ∆N-c-Raf. As more helices were deleted from the CRA domain, less binding of ∆N-c-Raf was
observed. However, two portions of the CRA domain seemed worth investigating, helices I and II,
and helices V and VI, since deletion of helices I and II (C1), and helices V and VI (C4C) resulted in a
sharp decrease in ∆N-c-Raf binding with the least amount of the CRA domain deleted.
Point mutations were designed to target the center of helices I and II, or helix V, in efforts to
disrupt the helical structures within the CRA domain and the binding interface between CRA and
∆N-c-Raf. Site-directed mutagenesis was used to create C4 with point mutations R625L and E626L
within helix I and II, denoted C4-R625L E626L, or with point mutations Q703L and T705L within helix
V, denoted C4-Q703L T705L. GST-C4-R625L E626L showed a significant loss in ∆N-c-Raf binding with
over threefold decrease compared to C4, whereas GST-C4-Q703L T705L did not disrupt the interaction,
showing only a slight decrease in ∆N-c-Raf binding (Figure 5C and Figure S2C). These results suggest
that the mutation R625L E626L made to helix I and II of the CRA domain, is sufficient to disrupt the
interaction between the CRA domain and ∆N-c-Raf in vitro.
To validate the in vitro binding data, mutant RanBPM CRA domains were cloned into the
mammalian expression vector pCMV, and co-transfected with pEBG-GST ∆N-c-Raf in HeLa RanBPM
shRNA cells. RanBPM- ∆C1 and RanBPM- R625L E626L were chosen to investigate their effect on
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∆N-c-Raf regulation. RanBPM-∆C1 showed significant loss of ∆N-c-Raf regulation, compared to WT
RanBPM, confirming our in vitro binding data (Figure 5D). However, the RanBPM R625L E626L point
mutant maintained the regulation of ∆N-c-Raf protein levels to a level comparable to WT RanBPM,
suggesting that the mutant could still interact with c-Raf in the cellular context. Similarly, the C4C
deletion (693–729) did not affect ∆N-c-Raf regulation when transfected in Hela RanBPM shRNA cells
(Figure S2D). This suggests that the interaction in vivo may be enhanced or stabilized by other domains
of RanBPM or by other members of the CTLH complex.
2.8. c-Raf Stability Is Regulated through the Proteasome and Its Ubiquitination Is Dependent on the
CTLH Complex
Since the CTLH complex has E3 ubiquitin ligase activity [24], we wanted to determine whether
it regulates c-Raf protein stability through the proteasomal degradation pathway. RanBPM shRNA
and control shRNA HeLa, and HCT116 cells were used to assess c-Raf protein levels in conditions of
proteasomal impairment in order to determine whether RanBPM loss of function would affect c-Raf
degradation. All cell lines were treated with either 10 µM of the proteasome inhibitor, MG132,
or with the vehicle, dimethyl sulfoxide (DMSO). HeLa and HCT116 cells expressing RanBPM
shRNA showed minimal accumulation of c-Raf protein levels during proteasomal inhibition, whereas
control shRNA cells exhibited a significant increase of c-Raf expression when compared to their
respective vehicle-treated controls (Figure 6A,B). This suggests that the downregulation of RanBPM
impairs proteasome-dependent degradation of c-Raf. To determine whether this could occur through
ubiquitination of c-Raf by the CTLH complex, we co-transfected control and RMND5A KO HeLa
cells with GST-∆N-c-Raf and HA-Ubiquitin constructs to investigate the involvement of RMND5A in
c-Raf ubiquitination. GST-∆N-c-Raf ubiquitination was observed in control Hela cells but was strongly
reduced in RMND5A KO cells confirming that the CTLH complex regulates c-Raf ubiquitination
(Figure 6C). Taken together, our data suggests that c-Raf ubiquitination and proteasomal degradation
is regulated by the CTLH complex.
2.9. The CTLH Complex Regulation Is Conserved for A- and B-Raf
The c-Raf region that interacts with the RanBPM/CTLH complex comprises the CR3 (Conserved
Region 3) which is the most conserved region between the three Raf isoforms and includes the kinase
domain [2]. Our observation that RanBPM shRNA cells display increased expression of A-Raf and
B-Raf (Figure 2B) prompted us to evaluate whether RMND5A could also regulate the levels of the other
two Raf kinases, A-Raf and B-Raf, which would confirm the involvement of the CTLH complex in the
regulation of all three Raf kinases. Indeed, levels of both A- and B-Raf were increased in RMND5A
KO cells (Figure 6D), with the most pronounced effect on A-Raf, which showed an almost threefold
increase compared to nearly twofold for B-Raf. This effect was not due to an isolated clonal effect,
as all RMND5A CRISPR KO clones obtained showed increased expression of the three Raf kinases
compared to wild-type cells (Figure S3). This suggests that the CTLH complex regulates all three Raf
kinases likely through a similar mechanism.
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Quantifications are shown below with error bar indicating SD, n = 8 for A-Raf, **** p < 0.0001 and n =
13 of 20
3 for B-Raf, ** p < 0.01.
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Based on the results obtained from this study, we propose a mechanism by which RanBPM
Based on the results obtained from this study, we propose a mechanism by which RanBPM
downregulates c-Raf through tethering c-Raf to the CTLH complex for ubiquitination. We showed
downregulates c-Raf through tethering c-Raf to the CTLH complex for ubiquitination. We showed
that both MAEA and RanBPM co-localize with c-Raf using PLA in HeLa cells. In addition, c-Raf
that both MAEA and RanBPM co-localize with c-Raf using PLA in HeLa cells. In addition, c-Raf
protein levels were affected by loss of CTLH complex members RMND5A and RanBPM. Deletion of
protein levels were affected by loss of CTLH complex members RMND5A and RanBPM. Deletion of
the CRA domain of RanBPM prevented c-Raf downregulation, suggesting the RanBPM CRA domain
the CRA domain of RanBPM prevented c-Raf downregulation, suggesting the RanBPM CRA domain
is essential for the targeting of c-Raf by the CTLH complex. In addition, deletion of RanBPM CRA
is essential for the targeting of c-Raf by the CTLH complex. In addition, deletion of RanBPM CRA
domain prevented the interaction between RanBPM and c-Raf and the RanBPM CRA domain alone
domain prevented the interaction between RanBPM and c-Raf and the RanBPM CRA domain alone
was capable of interacting directly with c-Raf. This suggests that RanBPM recruits c-Raf to the CTLH
was capable of interacting directly with c-Raf. This suggests that RanBPM recruits c-Raf to the CTLH
complex through a direct interaction with the CRA domain. Deletion of the LisH/CTLH domains
complex through a direct interaction with the CRA domain. Deletion of the LisH/CTLH domains also
also inhibited c-Raf downregulation; however, RanBPM still retained its ability to interact with c-Raf.
While the CTLH complex topology remains to be confirmed, studies of its yeast counterpart, the GID
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complex, have shown that RanBPM is connected to the other CTLH complex members through its
LisH and CTLH domains [40]. Therefore, the RanBPM LisH/CTLH deletion mutant would still retain
the ability to interact with c-Raf, but would no longer be able to connect c-Raf to the CTLH complex for
ubiquitination. Deletion of the N-terminus of RanBPM also resulted in a loss of c-Raf downregulation
while not interacting directly with c-Raf. RanBPM N-terminus is proline-rich and predicted to be an
unstructured, flexible region which could fold over to stabilize the protein or promote interactions
with other proteins [41]. The N-terminus could therefore be involved in stabilizing c-Raf interaction
with the CRA domain.
We were unable to identify a distinct motif in the CRA domain that mediates c-Raf interaction.
Our data suggest that each helix of the CRA domain has a role to play in c-Raf binding, with helices I,
II, V and VI being most important for the interaction. Site-directed mutagenesis was used to alter the
secondary structure of the CRA domain helices I and II or helix V in hopes of disrupting the interaction
between the CRA domain and c-Raf. In vitro binding data suggested that the amino acid substitutions
in helices I and II (R625L/E626L) were effective in disrupting this interaction. However, ectopically
expressed RanBPM-R625L/E626L was unable to downregulate ∆N-c-Raf, suggesting that the point
mutations did not disrupt the interaction between the CRA domain when tested in mammalian
cells. Our in vitro experiments employed CRA domain constructs lacking the central and N-terminal
portions of RanBPM. Therefore, the direct interaction of c-Raf with the RanBPM CRA domain may
be stabilized by additional interactions with the RanBPM N-terminal domain and/or other CTLH
complex members. It is worth noting that three other CTLH subunits, TWA1 and the two RING
domain subunits MAEA and RMND5A, also contain CRA domains [25], thus it is possible that these
subunits also help stabilize the c-Raf interaction with RanBPM.
We propose that c-Raf is targeted for degradation by the CTLH complex in a RanBPM-dependent
manner, with c-Raf being tethered to the complex by RanBPM through its CRA domain. RanBPM
is a promiscuous protein, reported to interact with over 75 proteins [23]. The ability of RanBPM to
associate with many proteins has given rise to the notion that it functions as an adaptor or scaffolding
protein and that it may function to bring substrate proteins into proximity of the complex [23,25,40].
Our data show that, in addition to c-Raf, both A- and B-Raf protein levels are regulated by the
CTLH complex. The c-Raf region interacting with RanBPM (∆N-c-Raf, aa 325–648) consists of little
more than the conserved region 3 (CR3) which is extremely well conserved between the three Raf
kinases and contains the kinase domain [2]. RanBPM could therefore interact with either of the Raf
kinases to target them for degradation, although an interaction between RanBPM and A- and B-Raf
remains to be demonstrated.
Four other E3 ubiquitin ligases have previously been shown to be involved in c-Raf ubiquitination/
degradation. The CHIP E3 ligase was shown to regulate c-Raf ubiquitination, however, CHIP
downregulation only partially affected c-Raf degradation suggesting that alternative mechanisms
exist involving (an) unidentified E3 ligase(s) [17]. The E3 ligase XIAP was shown to promote c-Raf
ubiquitination, but this occurred in a RING-independent manner, suggesting that XIAP does not target
c-Raf directly [15]. A recent study identified the E3 ubiquitin ligase HERC1 as a regulator of the ERK
pathway through a regulation of c-Raf stability [42]. HERC1 was shown to interact with c-Raf and
mediate c-Raf ubiquitination. Finally, the E3 ubiquitin ligase HUWE1, was also shown to regulate
c-Raf degradation, functioning indirectly through ubiquitination of the Raf scaffold protein Shoc2 [43].
Whether the CTLH complex directly targets c-Raf or targets other components of the c-Raf regulatory
complex remains to be investigated.
The functions and targets of the CTLH complex are still elusive, however several subunits of the
complex, studied in isolation, have been implicated in various cellular processes and regulations [23].
RanBPM in particular has been implicated in the regulation of several signaling pathways involved
in cancer development [22,23]. The basis for this study was our previous observation that RanBPM
downregulation correlated with ERK phosphorylation and pathway activation [21]. Our results
presented here suggest that RanBPM is the CTLH complex subunit that recruits c-Raf for degradation,
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therefore restricting the ERK pathway activation. This suggests a tumour-suppressive role for the CTLH
complex, which is further supported by the fact that loss of CTLH subunits promotes cell proliferation
and tumour growth in mice. What is unknown is how much of these effects are due to the ERK
pathway repression since the CTLH complex may be regulating many other pathways. In particular,
we have shown that the CTLH complex inhibits the activity of Histone Deacetylase 6 (HDAC6) [41,44],
a deacetylase known to promote many aspects of cell transformation and oncogenesis [45]. Other
pathways, such as the Src/Akt pathway and Transforming Growth Factor (TGF)-β signaling have been
shown to be inhibited by RanBPM [46,47] (reviewed in [22,23]). Understanding the full spectrum of
effects of the CTLH complex activity will require a better characterization of the activity of the complex
and the identification of its targets.
4. Materials and Methods
4.1. Plasmid Constructs
pCMV-HA-RanBPM and deletion mutants have been previously described [34,36]. pEBG-GST-∆N-c-Raf
was a gift from Dr. Zhijun Luo (Boston University, Boston, MA, USA). pET28a-∆N-c-Raf was generated
by isolating ∆N-c-Raf from pEBG-GST-∆N-c-Raf and subcloning into pET28a (EMD Millipore, Billerica,
MA, USA). pBSK-HA-Ubiquitin was a gift from Dr. Lina Dagnino (Western University, London,
ON, Canada). pCGN-HA-RMND5A was obtained by subcloning RMND5A cDNA obtained by
RT-PCR from a Jurkat T cell cDNA library into pCGN-HA plasmid. All pGEX4T1-GST-RanBPM
wild-type (WT) and mutant constructs were generated by polymerase chain reaction (PCR) and
subcloned in the pGEX4T1 vector (GE Healthcare Life Sciences, Little Chalfont, UK). RanBPM point
mutants (pGEX-4T-1-GST-C4 Q703L T750L and pCMV-HA-RanBPM R625L E626L) were generated by
site-directed mutagenesis. All PCR reactions were performed using KOD Hot Start Polymerase PCR
kit (EMD Millipore).
4.2. Cell Lines and Cell Culture and Transfections
HeLa and HEK293 cells were obtained from the American Type Culture Collection (Manassus,
VA, USA). Cells were grown in high-glucose DMEM supplemented with 10% FBS, 1% sodium
pyruvate, 1% L-glutamine, and 4.5 g/L glucose at 37 ◦ C and 5% CO2 . HeLa cell lines stably
expressing either RanBPM shRNA (clone 2–7) or control shRNA were previously described [34].
To generate HeLa and HEK293 RMND5A CRISPR/Cas9 knockout cells, guide RNA targeting exon
3 of RMND5A (top oligo: 50 -CACCGTGGAGCACTTCTTTCGACA-30 ; bottom oligo: 50 -AAACTGT
CGAAAGAAGTGCTCCAC-30 ) were cloned into pSpCas9(BB)-2A-Puro V2.0 (PX459). Forty-eight
hours after transfection, cells were put under puromycin selection (1.2 µg/mL for HEK293, 0.3 µg/mL
for HeLa) for seven days, followed by colony picking and expansion. The targeted region and the top
predicted off-target region were checked by sequencing for clone #1 which was used throughout this
study (Figure S4).
Mouse embryonic fibroblasts were prepared from E13.5 embryos according to standard protocols.
HEK293 cell growth rates were assessed as previously described [21] with WT HEK293 and RMND5A
KO clones #1, 3 and 14 (see Figure S3). A similar procedure was employed to evaluate MEFs growth
rates, except that cells were kept in serum-containing media.
For transfection experiments, ExGen 500 in vitro Transfection Reagent (Fermentas Thermo Fisher
Scientific Inc., Waltham, MA, USA), TurboFect Transfection Reagent (Thermo Fisher Scientific Inc.,
Waltham, MA, USA) and JetPRIME Transfection Reagent (PolyPlus Transfection, Illkirch, France) were
all used according to the manufacturer’s instructions. For each pCMV-HA RanBPM deletion mutant,
the amount of construct transfected was adjusted to account for variations in stability between the
expressed proteins. Transfected cells were incubated 24–48 h at 37 ◦ C in 5% carbon dioxide (CO2 ).

Int. J. Mol. Sci. 2019, 20, 934

16 of 20

4.3. In Situ Proximity Ligation Assay (PLA)
Duolink II (Sigma-Aldrich Inc., St. Louis, MO, USA) in situ proximity ligation assay (PLA) was
performed as previously described [48]. Cover slips were mounted onto glass slides with Prolong Gold
antifade reagent with DAPI (Molecular Probes by Life Technologies, Burlington, ON, Canada) and
were analyzed with an Olympus BX51 microscope (Olympus America Inc., Center Valley, PA, USA).
Images were captured using Image-Pro Plus v4.5 software (Media Cybernetics Inc., Bethesda, MD,
USA). The primary antibodies used were: c-Raf (1:50, E-10, Santa Cruz, Santa Cruz, CA, USA), Hsp90
(1:100, H-114, Santa Cruz), RanBPM (1:400, K-12, Santa Cruz), and MAEA (1:200, ab65239, Abcam,
Cambridge, UK).
4.4. Cell Extracts and Western Blot Analyses
For binding experiments, whole cell extracts (WCE) were prepared as described [21,34] and
for Western blot analyses, extracts were prepared in radioimmunoprecipitation assay (RIPA) buffer
(50 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM
EDTA) supplemented with 10 µg/mL aprotinin, 2 µg/mL leupeptin, 2.5 µg/mL pepstatin, 1 mM DTT,
2 mM NaF, 2 mM Na3VO4, and 0.1 mM PMSF. The cell lysates were centrifuged at 4 ◦ C for 20 min at
13,000 rpm.
Samples were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) on either 8% or 10% acrylamide gels and transferred onto a polyvinylidene fluoride
(PVDF) membrane, blocked in 5% non-fat dry milk in Tris Buffered Saline with Tween 20 (TBS-T) or in
Odyssey Blocking Buffer (Li-COR Biosciences, Lincoln, NE, USA), and hybridized with the following
antibodies: c-Raf (C-12, 1:500, Santa Cruz), HA (HA-7, 1:1000, Sigma–Aldrich, St. Louis, MO, USA),
RMND5A (NBP1–92337, 1:300, Novus Biologicals, Littleton, CO, USA), β-actin (I-19, 1:2000, Santa
Cruz), RanBPM (5M, 1:2000, Bioacademia, Osaka, Japan), GST (B-14, 1:500, Santa Cruz), A-Raf (1:500,
Cell Signaling Technology, Danvers, MA, USA, #4432), B-Raf (1:1000, Cell Signaling Technology #9434),
phospho-T202/Y204-ERK1/2 (1:2000, Cell Signaling #4370), ERK1/2 (1:1000, Cell Signaling #9102),
phospho-S217/221-MEK1/2 (1:2000, Cell Signaling #9154), MEK1/2 (1:1000, Cell Signaling #9122).
Following antibody incubations, blots were developed using either Western Lightning Enhanced
Chemiluminescence (ECL) Substrate (Perkin Elmer Inc., Waltham, MA, USA) or Clarity Western
ECL Substrate (Bio-Rad Laboratories Inc., Hercules, CA, USA). Images were captured using either
Kodak X-OMAR LS film (Carestream Health Inc., Rochester, NY, USA) or a ChemiDoc MP (Bio-Rad
Laboratories Inc.) and Image Lab software (Bio-Rad Laboratories Inc.).
4.5. GST Pull-Down Assays
For pull-down assays using Hela cell extracts, extracts were brought up to a final concentration of
0.4% NP40, 0.4% Triton X-100, 20 µg/mL aprotinin, 4 µg/mL leupeptin, 5 µg/mL pepstatin, 2 mM
DTT, 4 mM NaF, 4 mM NaVO4, and 0.2 mM PMSF and incubated with Glutathione-Agarose beads
(Sigma-Aldrich Inc., St. Louis, MO, USA) overnight at 4 ◦ C. Beads were subsequently washed three
times in WCE buffer supplemented with 0.4% NP40, 0.4% Triton X-100, 1 mM DTT and 0.1 mM PMSF,
resuspended and boiled in SDS loading dye and the resulting supernatant was collected and analyzed
by Western blot.
For pull-down assays using E. coli extracts, bacterial expression constructs were transformed into
E. coli strain BL21DE3. Protein expression was induced with 0.1 mM IPTG and extracts prepared lysed
in GST protein lysis buffer (25 mM HEPES pH 7.4, 100 mM KCl, 2 mM EDTA, and 20% glycerol).
Pull-downs were performed in binding buffer (15 mM HEPES pH 7.4, 60 mM KCl, 2 mM EDTA and
12% glycerol, 0.6% NP40, 0.6% Triton-X) for 2 h at 4 ◦ C with Glutathione-Agarose beads. Each sample
was then incubated with ∆N-c-Raf extracts for 2 h at 4 ◦ C and beads were washed with binding buffer
and analyzed by Western blot.
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For analyzing c-Raf ubiquitination, cells were co-transfected with pEBG-GST-∆N-c-Raf and
pBSK-HA-Ubiquitin. Twenty-four hours after transfection, cells were incubated with 10 µM MG132
(EMD-CalBiochem, San Diego, CA, USA) for 8 h. Cells were lysed in denaturing buffer (50 mM Tris,
pH 7.5, 150 mM NaCl, 1% Triton, 1% SDS, 1 mM Na3VO4, 10 mM NaF, and 5 mM NEM (N-Ethylamalide,
Bioshop Canada, Burlington, ON, Canada)), incubated on ice for 30 min, boiled for 10 min, and then back
on ice for 1 h. Lysates were diluted 1:5 in buffer A (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton, 1 mM
Na3VO4, 10 mM NaF, and 5 mM NEM) and incubated with Glutathione-Agarose beads for 2 h at 4 ◦ C.
Beads were then washed three times in buffer A, resuspended and boiled in SDS loading dye, and
analyzed by Western blot.
4.6. Mouse Tumour Models
Experiments were performed in accordance with the Canadian Council on Animal Care (CCAC)
guidelines approved by the Western University Animal Care Committee (AUP# 2017-140, 2/01/2018).
For subcutaneous injections, 500,000 cells in 100 µL of RPMI with Matrigel (1:1) were injected into the
right flank of 6–8 week old NOD/SCID/gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, NSG) mice
(The Jackson Laboratory). Tumour measurements were taken twice per week and a digital caliper was
used to measure Length × Width × Depth of the tumour upon excision in order to calculate volume.
Mice were fed regular chow of chow containing Doxocycline (0.625 g doxycyline hyclate/kg; TestDiet,
Richmond, IN, USA).
4.7. Statistical Analyses
One-way analysis of variance (ANOVA) with post-hoc Tukey test was performed to compare
multiple groups and two-sample t-test assuming unequal variance was performed to compare pairs
of groups. Graphed data are presented as mean ± standard error of the mean (SEM) or standard
deviation (SD), as indicated in figure legends and are determined to be significant when p < 0.05.
5. Conclusions
Our study reveals that Raf stability is regulated by the CTLH complex, a still poorly characterized
E3 ubiquitin ligase complex. We show that the CTLH complex subunit RanBPM directly binds to
c-Raf through its C-terminal CRA domain and that c-Raf ubiquitination and degradation is promoted
through the CTLH complex. We also provided evidence that this regulation may pertain to the related
kinases A- and B-Raf, suggesting a common mechanism of regulation of all three Raf kinases by the
CTLH complex. Finally, we show that loss of CTLH function through knockout of CTLH subunits
RMND5A and RanBPM promotes cell proliferation and tumour formation, suggesting that the CTLH
complex may restrict tumorigenesis at least in part through inhibition of the ERK pathway through a
control of c-Raf expression levels.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/4/
934/s1.
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Abbreviations
CHIP
CR3
CRA
CTLH
ELF3
ERK
Hsp90
KO
L1CAM
MAEA
RanBPM
RMND5A
RON
TG2
XIAP
WT

C-terminus of constitutive heat shock protein (Hsc) 70-interacting protein
Conserved Region 3
CT11-RanBPM
C-terminal to LisH (LIS1-homology motif)
E74-like factor 3
Extracellular signal-Regulated Kinase
Heat Shock Protein 90
Knockout
L1 cell adhesion molecule
Macrophage erythroblast attacher
Ran Binding Protein M
Required for Meiotic Nuclear Division 5A
Recepteur d’origine nantais
transglutaminase 2
X-linked inhibitor of apoptosis protein
Wild-type
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